Tolterodine clinical trials
Also written Detrol.
How each study uses tolterodine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tolterodine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Mar 1998 · DETROL · NDA 020771 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 26
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (10) · Astellas Pharma Inc (3) · Merck Sharp & Dohme LLC (3) · Far Eastern Memorial Hospital (3) · Samsung Medical Center (2) · Buddhist Tzu Chi General Hospital (2) · Kasr El Aini Hospital (1) · Yuzuncu Yil University (1)
Often tested with
Tested in the same studies.
Mirabegron (6) · Solifenacin (3) · Oxybutynin (2) · Doxazosin (2) · Vibegron (2) · Tadalafil (1) · Estradiol (1) · Pilocarpine (1)
Related medicines
As reviewed, each with the page that says it.
- One of Cholinergic Antagonists source
- One of Antimuscarinics source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tolterodine.
- May 2027TReating Incontinence for Underlying Mental and Physical HealthPhase 4 · University of California, San Francisco
Studies
Open first, then newest update. How each study uses tolterodine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 48
- TReating Incontinence for Underlying Mental and Physical HealthRecruitingPhase 4University of California, San FranciscoNCT05362292Written as Tolterodine Tartrate ERHow we know
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled TrialNot yet recruitingPhase 3Far Eastern Memorial HospitalNCT07114640Written as Tolterodine 4 mgHow we know
- Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled StudyRecruitingPhase 4Far Eastern Memorial HospitalNCT05946902Written as tolterodineHow we know
- A Study of YM178 in Subjects With Symptoms of Overactive BladderCompletedPhase 3Astellas Pharma IncNCT01043666Written as tolterodine ERHow we know
- Pharmacological vs Surgical Treatment for Mixed IncontinenceWithdrawnPhase 4Imperial College LondonNCT00523068Written as TolterodineHow we know
- Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.CompletedPhase 1Kasr El Aini HospitalNCT04500860Written as Tolterodine 4 Mg Oral Capsule, Extended ReleaseHow we know
- Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea SyndromeCompletedPhase 4Yuzuncu Yil UniversityNCT05250245Written as Tolterodine Tartrate 4 MGHow we know
- Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive BladderTerminatedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT01302938Written as Tolterodine ERHow we know
- Pharmacokinetics and Relative Bioavailability StudyCompletedPhase 1Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT01521767Written as tolterodine tartrateHow we know
- Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.CompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00230789Written as Tolterodine ER 4 mg QDHow we know
- A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.CompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00645281Written as tolterodine extended releaseHow we know
- Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in WomenCompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00143481Written as Tolterodine ER 4mg QDHow we know
- Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release TabletCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00139724Written as tolterodine extended release capsuleHow we know
- Detrol LA In Men With Overactive Bladder.CompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00282932Written as Detrol LAHow we know
- Effects Of Detrol LA On Memory And Cognition In Elderly PopulationCompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00411437Written as Tolterodine ERHow we know
- A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive BladderCompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00137397Written as Tolterodine ERHow we know
- Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.CompletedPhase 1Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00481728Written as TolterodineHow we know
- Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After SurgeryStatus unknownNot applicableXuanwu Hospital, BeijingNCT03280316Written as M receptor antagonistHow we know
- A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)CompletedPhase 4Astellas Pharma Global Development, Inc.NCT02138747Written as Tolterodine ERHow we know
- Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) PatientsCompletedPhase 4KYU-SUNG LEENCT00730535Written as TolterodineHow we know
See all 48 studies that test tolterodine →
Given beside what is tested · 6 — tolterodine is usual care or a partner of the new treatment
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.CompletedPhase 4Astellas Pharma IncNCT02294396Written as Tolterodine capsuleHow we know
- Genetic Determinants of Amitriptyline Efficiency for Pain TreatmentCompletedPhase 4Insel Gruppe AG, University Hospital BernNCT02256943Written as TolterodineHow we know
- Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part IICompletedPhase 4Insel Gruppe AG, University Hospital BernNCT02256956Written as TolterodineHow we know
- Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in WomenCompletedPhase 2Ferring PharmaceuticalsNCT01729819Written as Tolterodine tartrate extended release capsulesHow we know
- Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OABCompletedPhase 3SK Chemicals Co., Ltd.NCT02485067Written as Detrusitol 2mg tabletHow we know
- Behavior Enhances Drug Reduction of Incontinence (BE-DRI)CompletedNot applicableCarelon ResearchNCT00090584Written as TolterodineHow we know
As the comparator · 22 — what is tested is compared with tolterodine
- Non-invasive Saphenous Nerve Stimulation Therapy for Overactive BladderNot yet recruitingPhase 3NinaMED Pty LtdNCT07780786Written as tolterodine tartrate 4 mg extended releaseHow we know
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedPhase 3Astellas Pharma IncNCT00689104Written as TolterodineHow we know
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedPhase 3Astellas Pharma IncNCT00688688Written as TolterodineHow we know
- A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive BladderCompletedPhase 3Astellas Pharma IncNCT00966004Written as tolterodineHow we know
- Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive BladderCompletedPhase 2Astellas Pharma Europe B.V.NCT01604928Written as tolterodineHow we know
- Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive BladderStatus unknownPhase 4China Medical University HospitalNCT04909255Written as oxybutynin, tolterodine, solifenacinHow we know
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).CompletedPhase 3Urovant Sciences GmbHNCT03583372Written as Tolterodine Tartrate ERHow we know
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)CompletedPhase 3Urovant Sciences GmbHNCT03492281Written as Tolterodine Tartrate ERHow we know
- Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.CompletedPhase 3R-PharmNCT03575702Written as Urotol®How we know
- Treatment of Incontinence Without Memory ProblemsCompletedPhase 4University of California, San FranciscoNCT02436889Written as Tolterodine TartrateHow we know
- Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in WomenCompletedNot applicableShanghai Institute of Acupuncture, Moxibustion and MeridianNCT02723279Written as TTHow we know
- Combined Behavioral and Drug Treatment of Overactive Bladder in MenCompletedPhase 2/3University of Alabama at BirminghamNCT01175382Written as Tolterodine + tamsulosinHow we know
- SSR240600C Treatment in Women With Overactive BladderCompletedPhase 2SanofiNCT00564226Written as tolterodineHow we know
- Study of Herbmed Plus in Ureteral Stent DiscomfortCompletedPhase 2Dr .S.B.PATANKARNCT01356355Written as TolterodineHow we know
- Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)CompletedPhase 3PfizerNCT00444925Written as tolterodine tartrateHow we know
- Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy SubjectsCompletedPhase 1NovartisNCT00703703Written as TolterodineHow we know
- Study of ONO-8539 in Patients With Overactive BladderCompletedPhase 2Ono Pharmaceutical Co. LtdNCT00876421Written as TolterodineHow we know
- MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.CompletedPhase 2SanofiNCT00174798Written as TolterodineHow we know
- Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.CompletedPhase 3PfizerNCT00611026Written as Tolterodine ERHow we know
- A Confirmatory Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01004315Written as TolterodineHow we know
Showing 20 of 22.
Codes
What other systems call tolterodine · ClinicalTrials.gg INT006535
- MeSH (NLM) D000068737Tolterodine TartrateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WHE7A56U7KTOLTERODINEConfirmed FDA, NLM, Wikidata
- RxNorm 119565Confirmed FDA, Wikidata
- Wikidata Q424312tolterodineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62083TolterodineOne source FDA
- DrugBank DB01036One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068737 | Tolterodine Tartrate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WHE7A56U7K | TOLTERODINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 119565 | — | Confirmed FDA, Wikidata |
| Wikidata | Q424312 | tolterodine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62083 | Tolterodine | One source FDA |
| DrugBank | DB01036 | — | One source Wikidata |
Also registered as tolterodine tartrate (UNII 5T619TQR3R · RxNorm 221174).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.